SCHEMBL3010126

SCHEMBL3010126

Cc1cccc(-c2csc(N3CCC(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.56
RAB9A P51151 6/20 0.56
NPC1 O15118 5/20 0.48
MAPT P10636 6/20 0.44
KDM1A O60341 4/20 0.44
MAOA P21397 4/20 0.44
MAPK1 P28482 2/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 3/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 3/20 0.43
HTT P42858 2/20 0.43
KDM4E B2RXH2 1/20 0.43
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALOX12 P18054 1/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013868 0.94 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1MAPTMAPK1
SCHEMBL3013271 0.93 RAB9A (0.52) SMN1; SMN2RAB9ANPC1MAPTKDM1A
SCHEMBL3015000 0.91 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1MAPTKDM1A
SCHEMBL3019424 0.91 SMN1; SMN2 (0.52) SMN1; SMN2RAB9ANPC1MAPTKDM1A
SCHEMBL3015016 0.90 RAB9A (0.58) SMN1; SMN2RAB9ANPC1MAPTKDM1A
SCHEMBL3016248 0.90 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1MAPTMAPK1
SCHEMBL3013830 0.90 RAB9A (0.53) SMN1; SMN2RAB9ANPC1MAPTKDM1A
SCHEMBL2999993 0.89 RAB9A (0.59) SMN1; SMN2RAB9ANPC1MAPTKDM1A
SCHEMBL3016163 0.89 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1MAPTMAPK1
SCHEMBL3013465 0.89 RAB9A (0.50) SMN1; SMN2RAB9ANPC1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.